Stockscreener 앱 받기
11.24
2.84%
0.31
시간 외 거래:
11.24
전일 마감가:
$10.93
열려 있는:
$10.94
하루 거래량:
274.51K
Relative Volume:
0.32
시가총액:
$612.99M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.41%
1개월 성능:
+20.60%
6개월 성능:
-6.95%
1년 성능:
+0.00%
1일 변동 폭
$10.94
$11.41
1주일 범위
$10.03
$12.13
52주 변동 폭
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-785-8308
주소
245 MAIN STREET, CAMBRIDGE
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
11.24 | 555.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Is Bicara Therapeutics Inc. a good long term investmentExplosive returns - Autocar Professional
What drives Bicara Therapeutics Inc. stock priceHigh-octane investment gains - Autocar Professional
What analysts say about Bicara Therapeutics Inc. stockHigh-octane gains - PrintWeekIndia
Bicara Therapeutics Inc. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86 - Defense World
How Bicara Therapeutics Inc. stock performs during market volatilityTop Performing Stocks - Newser
Why Bicara Therapeutics Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
What makes Bicara Therapeutics Inc. stock price move sharplyInvestor Friendly Risk Reward - Newser
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Yahoo Finance
GAMMA Investing LLC Purchases 7,694 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks
Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals
# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com
Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World
Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN
Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock - Investing.com
Bicara Therapeutics Expands Boston Headquarters with New Lease - TipRanks
25,028 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Merus Raises $300m After ASCO Success - insights.citeline.com
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Cantor Fitzgerald maintains overweight rating on Bicara stock By Investing.com - Investing.com India
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target - TipRanks
Cantor Fitzgerald maintains overweight rating on Bicara stock - Investing.com
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock - Investing.com India
Stifel reiterates Buy rating on Bicara Therapeutics stock - Investing.com Australia
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):